Cell Therapeutics works in the field of cancer, searching for cures and treatments that can cure each patient individually. The company seeks to find or make the right medication to treat the patient’s cancer, however the company was reported by the U.S. drug reviewers, Monday, for an experimental lymphoma drug and said the medicine had substantial side effects. Recently Cell Theraperutics has been trying to appeal to the FDA to sell pixantrone under the brand name Pixuvri for treating non-Hodgkin’s lymphoma that has stopped responding to other treatments. During a study with 20 percent of patients using pixantrone passed the goal to have a major decrease in their disease, compared to about 6 percent of patients who used a different medicine.
On Wednesday the FDA will present the drug, with all its risks and benefits, before the advisory panel, to decide if the drug can be approved.
